CatSci Launch SmartPath - An Innovative Digital API Risk Assessment
CatSci Ltd are incredibly proud to announce the launch of SmartPath – an innovative digital tool
created by CatSci that will risk assess our customers’ API, project, and formulation data and offer
them smart mitigation strategies.
With the premium SmartPath feature, you will work alongside our Director of Material Sciences, Dr
Robert Dennehy, to devise a tailored life-cycle plan of your API to meet your budget and project
needs. So, you can focus on what matters most - delivering your asset to the next step, without
surprises or delays.
De-risking your pharmaceutical pipeline is our mission, and SmartPath is here to make that a reality.
Dr Robert Dennehy said: “At CatSci, we are very excited about SmartPath. In late development, it’s
very common to firefight problems created through poor decisions around the API and formulation.
The paradox is that we very often know the characteristics of projects that might turn into ‘problem
children.’ SmartPath is a way of collating this information so it becomes directional and can be used
rather than just ignored. SmartPath helps identify risks and their mitigations that are appropriate for
the development phase of the drug.”
To celebrate the launch of SmartPath, we are hosting a free virtual symposium on 21st June 2022,
where we are excited to share more about the digital tool.
The event is titled “A Medicine Is More Than A Molecule” and will explore the crucial role that
material science and solid-state properties of pharmaceutical materials play in success, as well as
how SmartPath can help you rapidly take the right steps to accomplish your project objectives.
You can find the agenda here.
Register for the free virtual event today.
© CatSci Ltd, 2022.
For more information, including media enquiries, please contact:
Tel: +44 330 025 0170